InvestSMART

Australian Clinical Labs Limited (ASX: ACL) - Announcements

- Current share price for ACL : $2.880

ASX company news and announcements for Australian Clinical Labs Limited (ACL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Australian Clinical Labs Limited (ACL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Australian Clinical Labs Limited (ACL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Australian Clinical Labs Limited (ACL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$537 Fondaparinux Update 22 Nov 2012 8:29AM $0.580 $2.880 risen by 396.55%
$537 DSMB Recommends Continuation of Phase III Clinical Trial 8 Nov 2012 8:30AM $0.545 $2.880 risen by 428.44%
$537 Appendix 4C - quarterly 30 Oct 2012 9:03AM $0.550 $2.880 risen by 423.64%
$537 Adjournment of Scheme and General Meetings 5 Oct 2012 10:22AM $0.550 $2.880 risen by 423.64%
$537 HA-Irinotecan Phase III Clinical Trial Update 25 Sep 2012 8:38AM $0.495 $2.880 risen by 481.82%
$537 Fondaparinux Update 24 Sep 2012 8:49AM $0.480 $2.880 risen by 500%
$537 Scheme Booklet 28 Aug 2012 7:29PM $0.505 $2.880 risen by 470.30%
$537 Correction of Annual Results Announcements 22 Aug 2012 2:59PM $0.530 $2.880 risen by 443.40%
$537 Trading Halt 22 Aug 2012 10:36AM $0.530 $2.880 risen by 443.40%
$537 Preliminary Final Report 22 Aug 2012 8:25AM $0.530 $2.880 risen by 443.40%
$537 Appendix 4C - quarterly 31 Jul 2012 9:56AM $0.495 $2.880 risen by 481.82%
$537 Fondaparinux Update 31 Jul 2012 9:52AM $0.495 $2.880 risen by 481.82%
$537 Proposed Demerger Of Alchemia's Oncology Business 9 Jul 2012 8:14AM $0.545 $2.880 risen by 428.44%
$537 Open Briefing 23 May 2012 9:54AM $0.470 $2.880 risen by 512.77%
$537 HA-Irinotecan Phase 3 Trial Update 22 May 2012 8:31AM $0.470 $2.880 risen by 512.77%
$537 Fondaparinux Update 14 May 2012 10:09AM $0.450 $2.880 risen by 540%
$537 Appendix 4C - quarterly 19 Apr 2012 3:16PM n/a $2.880 n/a
$537 Phase III Clinical Trial Update 13 Apr 2012 9:57AM $0.525 $2.880 risen by 448.57%
$537 Grant of US Patent For Fondaparinux Manufacturing Process 29 Feb 2012 10:20AM $0.440 $2.880 risen by 554.55%
$537 Appendix 4D 15 Feb 2012 2:48PM n/a $2.880 n/a
$537 Fondaparinux Update 6 Feb 2012 8:27AM $0.350 $2.880 risen by 722.86%
$537 Appendix 4C - quarterly 23 Jan 2012 9:58AM $0.320 $2.880 risen by 800%
$537 $15m Placement SPP and proposed De-merger 7 Nov 2011 10:04AM $0.305 $2.880 risen by 844.26%
$537 Trading Halt 3 Nov 2011 9:31AM $0.275 $2.880 risen by 947.27%
$537 Fondaparinux Update 27 Oct 2011 8:26AM $0.285 $2.880 risen by 910.53%

876 - 900 of 1019 results

Page 36 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.